ANIK
ANIK
NASDAQ · Biotechnology

Anika Therapeutics Inc

$13.81
-0.14 (-1.00%)
As of Nov 14, 2:22 AM ET ·
Financial Highlights (FY 2026)
Revenue
104.02M
Net Income
-10,031,881
Gross Margin
56.6%
Profit Margin
-9.6%
Rev Growth
-10.3%
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 56.6% 56.6% 28.3% 28.3%
Operating Margin -9.8% -8.8% 27.9% 28.4%
Profit Margin -9.6% -9.2% 22.9% 26.9%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 104.02M 115.94M 23.45M 26.68M
Gross Profit 58.83M 65.58M 6.64M 7.56M
Operating Income -10,194,019 -10,225,832 6.55M 7.58M
Net Income -10,031,881 -10,063,188 5.38M 7.18M
Gross Margin 56.6% 56.6% 28.3% 28.3%
Operating Margin -9.8% -8.8% 27.9% 28.4%
Profit Margin -9.6% -9.2% 22.9% 26.9%
Rev Growth -10.3% -10.3% -4.1% +21.0%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 38.69M 41.86M
Total Equity — — 99.18M 96.99M
D/E Ratio — — 0.39 0.43
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -5,236,726 -5,544,906 8.65M 11.22M
Free Cash Flow — — 4.59M 6.09M